Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers
Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.
Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer
Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512